Feature | VIVA | November 14, 2019

VIVA 2019 Late-breaking Clinical Trials

The latest clinical data in vascular medicine and peripheral vascular interventions

Viva conference late breaking clinical trials, #VIVA19 #VIVA #VIVA2019

November 14, 2019 — The results of the 21 late-breaking clinical trials presented for the first time at Vascular Interventional Advances (VIVA) 2019 conference. These results were presented in four different sessions on Nov. 5-6, 2019, in VIVA's Global Theater. VIVA highlights the latest science in vascular and peripheral vascular interventions.
 

Tuesday Late-breakers, November 5:

   • No Increased Mortality for the Zilver PTX Drug-Eluting Stent Compared to Uncoated Devices, presented by Michael Dake, M.D.

   • A Novel Sustained Sirolimus Release Eluting Balloon: 2-Year Data From the SELUTION SFA Trial, presented by Thomas Zeller, M.D., Ph.D.

   • RANGER II SFA: Randomized Trial of RANGER DCB vs. PTA in the SFA, presented by Ravish Sachar, M.D.

   • 4-Year Outcomes From the IN.PACT Global Study, presented by Thomas Zeller, M.D., Ph.D.

   • DCB vs POBA After B-laser Atherectomy Shows No Difference, presented by John Rundback, M.D.

   • Two-Year Outcomes From the IMPERIAL Randomized Trial of Eluvia and Zilver PTX, presented by Osamu Iida, M.D.

 

   • Full Cohort 24-Month Safety and Efficacy Results of the VMI-CFA Common Femoral Stenting Trial, presented by Koen Deloose, M.D.

   • Nexus Aortic Arch Branch Stent-Graft System – Mid-Term Results, presented by Mario Lachat, M.D.

   • Revolution Rotational Atherectomy System IDE Experience, presented by Jeffrey Carr, M.D.

   • 1-year Results From the MIMICS-3D Registry: Investigating the BioMimics 3D Stent, presented by Michael Lichtenberg, M.D.

   • Treatment of BTK Disease With a Novel Device: Update on the DEEPER OUS Trial, presented by Thomas Zeller, M.D., Ph.D.

 

Wednesday Late-breakers, November 6:

   • 6-Months Results of TOBA II BTK, presented by George Adams, M.D.

   • 5-Year ABSORB BTK Trial Results, presented by Ramon Varcoe, MBBS, MS, Ph.D.

   • Results of the PROMISE I Trial Using the LimbFlow Bypass System in Limb-threatening Ischemia, presented by Daniel Clair, M.D.

   • Initial 12-Month Outcomes From the TANGO Trial (Adventitial Temsirolimus in BTK Lesions), presented by Ehrin Armstrong, M.D.

   • The Ulysse Registry Shows Benefit of Ultrasoundplasty in Below-the-knee Interventions, presented by Costantino Del Giudice, M.D., Ph.D.

    
   • IN.PACT AV Access 6-month Lesion Outcomes, presented by Robert Lookstein, M.D., MHCDL

   • Lateral Subdermic Plexus Insufficiency: A Paradigm Shift With Restless Leg Syndrome, presented by Swar Shah, M.D.

   • Early Outcomes From the ClotTriever (CLOUT) Registry in DVT, presented by David Dexter, M.D.

   • Indigo Aspiration System for Acute Pulmonary Embolism, presented by Akhilesh Sista, M.D.

   • 1-Year Results of the DISAPEAR Registry, presented by Steven Kum, M.D.

 

 
Related Late-breaking Cardiovascular Trials:

ACC 2019 Late-breaking Presentations

Late-breaking Interventional Cardiology Presentations at SCAI 2019

American Heart Association 2018 Late-breaking Trials

TCT 2019 Late-breaking Presentations

American Heart Association 2019 Late-breaking Trials

Related Content

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone. #SCAI21 #SCAI2021 Creating a card0-renal program.

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone.

Feature | Cath Lab | May 14, 2021 | By Dave Fornell, Editor
There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal fun
Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting proc

Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting procedures.

News | Cath Lab | May 12, 2021
May 12, 2021 — Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has
SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI heart attack. #SCAI21 #SCAI2021

SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI.

Feature | Cath Lab | May 06, 2021 | By Dave Fornell, Editor
April 29, 2021 — Here is the list of late-breaking study presentations and links to articles about each of them from
Most Stable Ischemic Heart Disease Patients Did Not Meet ISCHEMIA Trial Enrollment Criteria, raising questions about its application in real-world practice. #SCAI2021 Getty Images

Getty Images

News | Cath Lab | May 03, 2021
May 3, 2021 – Results from a new study find a broad range of patients who typically undergo revascularization for sta
New study demonstrates depression, HIV, mental health, obesity, alcohol and drug abuse are risk factors on most common type of heart disease in young black patients. Photo by Dave Fornell
News | Cath Lab | April 29, 2021
April 29, 2021 – A retrospective analysis of risk factors for coronary artery disease (CAD) in young African American
There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

News | Cath Lab | April 28, 2021
April 28, 2021 – Results from a retrospective observational study, presented today at...
A cardiac cath lab at Henry Ford Hospital in Detroit. Photo by Dave Fornell

A cardiac cath lab complex PCI case at Henry Ford Hospital in Detroit. Photo by Dave Fornell

News | Cath Lab | April 28, 2021
Videos | Cath Lab | April 02, 2021
Corindus, a Siemens Healthineers company and a developer of vascular robotics, recently launched a new set of automat
Videos | Cath Lab | March 31, 2021
This is a quick example of clinical use of the Shockwave Medical Intravascular Lithotripsy system that uses sonic wav